One of the most stubborn obstacles to an HIV cure is understanding exactly which cells hide replication-competent virus during antiretroviral therapy. New mechanistic data suggest that hepatitis C virus coinfection doesn't just passively correlate with larger HIV reservoirs — it may actively expand them by creating a highly permissive cellular niche that persists even after HCV is cleared.
This cross-sectional study enrolled 20 people with chronic HCV infection and 20 uninfected controls, examining how HCV shapes CD4+ T-cell vulnerability to HIV-1. Memory CD4+ T-cells from the HCV-infected group showed significantly greater permissiveness to productive HIV-1 infection in laboratory conditions (p = 0.03), and this susceptibility scaled directly with circulating HCV-RNA levels (r = 0.491, p = 0.046). The cellular mechanism centers on a distinctive surface-receptor profile on HCV-specific CD4+ T-cells: co-expression of CCR5 (the primary HIV-1 entry co-receptor), CXCR6 (a liver-homing marker), and CCR6 (associated with Th17 lineage cells). This phenotype distinguishes HCV-reactive cells from CD4+ T-cells targeting other pathogens such as cytomegalovirus. Critically, in a longitudinally tracked HCV/HIV co-infected individual on ART, HCV-specific CD4+ T-cells carried replication-competent HIV during acute HCV reinfection, with integrated HIV-DNA persisting after viral resolution.
These findings carry meaningful implications for HIV cure research. Th17-lineage, CCR5+ CD4+ T-cells have previously been identified as disproportionate contributors to the HIV reservoir, particularly in gut-associated lymphoid tissue, and this work extends that logic to pathogen-specific responses in a coinfection context. A key limitation is the small cohort size — 20 per group — and the reliance on a single longitudinal case study for the replication-competent reservoir data, which limits causal inference. The in vitro permissiveness data, while compelling, may not fully replicate the immune microenvironment in vivo. Still, the mechanistic specificity here — receptor phenotyping tied to functional reservoir assays — elevates this beyond descriptive epidemiology and points toward antigen-specific reservoir seeding as a genuine therapeutic target.